Phenotype
|
Fish
|
Conditions
|
Figures
|
locomotory behavior process quality, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: tauroursodeoxycholic acid
|
Figure 4
from Naef et al., 2021
|
retinal pigmented epithelium decreased thickness, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 1
from Naef et al., 2025
|
whole organism sacs expression decreased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Figure 1
from Naef et al., 2021
|
whole organism vim expression decreased amount, abnormal
|
sacsirc1/irc1
|
chemical treatment by environment: N-acetyl-L-leucine
|
Figure 5
from Naef et al., 2021
|
cranial nerve II increased thickness, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 3
from Naef et al., 2025
|
detection of light stimulus involved in visual perception increased sensitivity of a process detection of light stimulus, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 6
from Naef et al., 2025
|
retinal cone cell morphology, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 5
from Naef et al., 2025
|
eye area, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: N-acetyl-L-leucine
|
Figure 5
from Naef et al., 2021
|
retinal inner nuclear layer decreased thickness, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 1
from Naef et al., 2025
|
locomotory behavior process quality, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: N-acetyl-L-leucine
|
Figure 4
from Naef et al., 2021
|
Muller cell morphology, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 8
from Naef et al., 2025
|
whole organism vim expression decreased amount, abnormal
|
sacsirc1/irc1
|
chemical treatment by environment: tauroursodeoxycholic acid
|
Figure 5
from Naef et al., 2021
|
whole organism ttpa expression decreased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 7
from Naef et al., 2025
|
eye decreased area, abnormal
|
sacsirc1/irc1
|
control
|
Figure 5
from Naef et al., 2021
|
visual behavior disrupted, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 2
from Naef et al., 2025
|
whole organism suox expression increased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 7
from Naef et al., 2025
|
whole organism mitochondrion decreased functionality, abnormal
|
sacsirc1/irc1
|
control
|
Figure 3 ,
Figure 5
from Naef et al., 2021
|
eye decreased size, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 1
from Naef et al., 2025
|
whole organism mitochondrion functionality, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: tauroursodeoxycholic acid
|
Figure 5
from Naef et al., 2021
|
optomotor response process quality, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 2
from Naef et al., 2025
|
whole organism apoptotic process occurrence, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: N-acetyl-L-leucine
|
Figure 5
from Naef et al., 2021
|
retinal ganglion cell layer apoptotic process increased occurrence, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 4
from Naef et al., 2025
|
retina inflammatory response increased occurrence, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 8
from Naef et al., 2025
|
retinal ganglion cell layer decreased thickness, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 1
from Naef et al., 2025
|
swimming decreased linear velocity, abnormal
|
sacsirc1/irc1
|
control
|
Figure 2 ,
Figure 4
from Naef et al., 2021
|
visually-mediated background adaptation disrupted, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 1
from Naef et al., 2025
|
retina dysplastic, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 5
from Naef et al., 2025
|
whole organism apoptotic process increased occurrence, abnormal
|
sacsirc1/irc1
|
control
|
Figure 5
from Naef et al., 2021
|
Purkinje cell ab1-pvalb7 labeling decreased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Figure 2
from Naef et al., 2021
|
whole organism vkorc1 expression increased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 7
from Naef et al., 2025
|
retina mitotic M phase increased duration, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 3
from Naef et al., 2025
|
swimming process quality, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: tauroursodeoxycholic acid
|
Figure 4
from Naef et al., 2021
|
amacrine cell ab1-elavl labeling increased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 5
from Naef et al., 2025
|
eye decreased size, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Figure 1
from Naef et al., 2021
|
whole organism calr expression increased amount, abnormal
|
sacsirc1/irc1
|
chemical treatment by environment: N-acetyl-L-leucine
|
Figure 5
from Naef et al., 2021
|
whole organism reactive oxygen species increased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Figure 3
from Naef et al., 2021
|
retinal inner nuclear layer apoptotic process increased occurrence, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 4
from Naef et al., 2025
|
whole organism vim expression increased amount, abnormal
|
sacsirc1/irc1
|
control
|
Figure 3 ,
Figure 5
from Naef et al., 2021
|
swimming process quality, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: N-acetyl-L-leucine
|
Figure 4
from Naef et al., 2021
|
locomotory behavior decreased process quality, abnormal
|
sacsirc1/irc1
|
control
|
Figure 2 ,
Figure 4
from Naef et al., 2021
|
eye apoptotic process increased occurrence, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Figure 3
from Naef et al., 2021
|
retina cell population proliferation increased occurrence, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 3
from Naef et al., 2025
|
Muller cell ab-4c4 labeling spatial pattern, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 8
from Naef et al., 2025
|
retinal outer nuclear layer apoptotic process increased occurrence, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 4
from Naef et al., 2025
|
retina layer formation process quality, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 1
from Naef et al., 2025
|
retina Ab22-gfap labeling increased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 8
from Naef et al., 2025
|
retinal outer nuclear layer decreased thickness, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 1
from Naef et al., 2025
|
Muller cell glial cell activation increased occurrence, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 8
from Naef et al., 2025
|
retinal rod cell morphology, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 5
from Naef et al., 2025
|
retinal rod cell ab3-rho labeling increased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 5
from Naef et al., 2025
|
whole organism calr expression decreased amount, abnormal
|
sacsirc1/irc1
|
control
|
Figure 3 ,
Figure 5
from Naef et al., 2021
|
whole organism calr expression amount, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: tauroursodeoxycholic acid
|
Figure 5
from Naef et al., 2021
|
retina decreased thickness, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 1
from Naef et al., 2025
|
whole organism mitochondrion functionality, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: N-acetyl-L-leucine
|
Figure 5
from Naef et al., 2021
|
retina apoptotic process increased occurrence, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 4
from Naef et al., 2025
|
amacrine cell increased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 5
from Naef et al., 2025
|
whole organism ab2-sqstm1 labeling decreased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Figure 3
from Naef et al., 2021
|
whole organism rdh5 expression decreased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 7
from Naef et al., 2025
|
whole organism apoptotic process occurrence, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: tauroursodeoxycholic acid
|
Figure 5
from Naef et al., 2021
|
whole organism epx expression increased amount, abnormal
|
sacsirc1/irc1
|
standard conditions
|
Fig. 7
from Naef et al., 2025
|
eye area, ameliorated
|
sacsirc1/irc1
|
chemical treatment by environment: tauroursodeoxycholic acid
|
Figure 5
from Naef et al., 2021
|
Purkinje cell decreased amount, abnormal
|
sacsirc1/irc1; bz6Tg
|
standard conditions
|
Figure 2
from Naef et al., 2021
|
cerebellum decreased area, abnormal
|
sacsirc1/irc1; bz6Tg
|
standard conditions
|
Figure 2
from Naef et al., 2021
|